

# Michael Schuster

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8605885/publications.pdf>

Version: 2024-02-01

12  
papers

1,158  
citations

1039406

9  
h-index

1199166

12  
g-index

12  
all docs

12  
docs citations

12  
times ranked

2715  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. <i>Nature Metabolism</i> , 2021, 3, 149-165.	5.1	378
2	Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. <i>Blood</i> , 2016, 127, 325-332.	0.6	228
3	Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	203
4	Acute BAF perturbation causes immediate changes in chromatin accessibility. <i>Nature Genetics</i> , 2021, 53, 269-278.	9.4	103
5	MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. <i>Nature Genetics</i> , 2019, 51, 990-998.	9.4	61
6	Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. <i>Blood</i> , 2019, 134, 199-210.	0.6	54
7	RANK links thymic regulatory T cells to fetal loss and gestational diabetes in pregnancy. <i>Nature</i> , 2021, 589, 442-447.	13.7	52
8	Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. <i>Nature Chemical Biology</i> , 2016, 12, 504-510.	3.9	43
9	Mutations and variants of ONECUT1 in diabetes. <i>Nature Medicine</i> , 2021, 27, 1928-1940.	15.2	24
10	<i>PD-L1</i> overexpression correlates with <i>JAK2</i> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 390-400.	2.0	8
11	EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity. <i>Leukemia</i> , 2021, 35, 1521-1526.	3.3	3
12	High-throughput drug screening identifies the ATR-CHK1 pathway as a therapeutic vulnerability of CALR mutated hematopoietic cells. <i>Blood Cancer Journal</i> , 2021, 11, 137.	2.8	1